|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
MGD |
|
|
|
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer susceptibility gene 1 (BRCA1) and binding partner BRCA1-associated RING domain protein 1 (BARD1) form an essential E3 ubiquitin ligase important for DNA damage repair and homologous recombination.
|
30383767 |
2018 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
BARD1 is indispensable for cell viability, so loss-of-function mutations are rare, but mutations and truncations that alter its function might be involved in the pathogenesis of breast cancer.
|
16633366 |
2006 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
BARD1 Cys557Ser was associated with an increased BC risk (P = 0.04, OR = 3.4 [95 % CI 1.2-10.2]) among cases belonging to families with a strong family history of BC.
|
22544576 |
2012 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
BARD1 is a breast cancer tumor suppressor with multiple domains and functions.
|
26022179 |
2015 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
BARD1 is expressed as splice variant isoforms in breast cancer.
|
27477900 |
2016 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
BARD1-mutated BC index patients showed a significantly younger mean age at first diagnosis (AAD; 42.3 years, range 24-60 years) compared with the overall study sample (48.6 years, range 17-92 years; P = 0.00347).
|
31036035 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
A blood test based on BARD1, a protein that interacts with the breast cancer gene product BRCA1, is a promising candidate for fulfilling these conditions.
|
19959210 |
2010 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
A homologue of the breast cancer-associated gene BARD1 is involved in DNA repair in plants.
|
16957774 |
2006 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
A significant proportion of BRCA1 tumours were positive for PARP1 (non-cleaved), and negative for BARD1 and RAD51 compared with sporadic BC.
|
25690937 |
2015 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
After exclusion of BRCA1, BRCA2, and syndromic breast cancer genes (CDH1, PTEN, and TP53), observed pathogenic variants in 5 of 16 genes were associated with high or moderately increased risks of breast cancer: ATM (OR, 2.78; 95% CI, 2.22-3.62), BARD1 (OR, 2.16; 95% CI, 1.31-3.63), CHEK2 (OR, 1.48; 95% CI, 1.31-1.67), PALB2 (OR, 7.46; 95% CI, 5.12-11.19), and RAD51D (OR, 3.07; 95% CI, 1.21-7.88).
|
28418444 |
2017 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Because BARD1 associates via its NH2-terminal RING domain with the breast cancer susceptibility gene BRCA1 that provides a platform for interactions with proteins involved in DNA repair and checkpoint control, our results provide a link between the Ewing's sarcoma gene product and the genome surveillance complex.
|
12183411 |
2002 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Bioinformatics analysis revealed that BARD1 may be a predictive biomarker for prognosis of breast cancer.
|
31808361 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
BRCA1 and BARD1 expressions were performed by immunohistochemistry and immunofluorescence in 103 breast cancer tumors.
|
26395808 |
2015 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 or BRCA2 mutations were found in 7.3% of the subjects, 6.3% had a mutation in other breast cancer genes (PALB2, CHEK2, ATM, and BARD1), and 1.6% had mutations in genes not associated with breast cancer.
|
30933323 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
BRCA1-associated RING domain (BARD1) was identified as a protein interacting with the breast cancer gene product BRCA1.
|
9832560 |
1998 |
|
Malignant neoplasm of breast
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
BRCA1-dependent and independent functions of BARD1.
|
11943588 |
2002 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
|
21344236 |
2012 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
|
20077502 |
2010 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer.
|
26546047 |
2016 |
|
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the common Icelandic BRCA2 999del5 mutation were found to have their risk of breast cancer further increased if they also carried the BARD1 variant: the frequency of the BARD1 variant allele was 0.047 (OR = 3.11, 95% CI 1.16-8.40, p = 0.046) in 999del5 carriers with breast cancer.
|
16768547 |
2006 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
CircRNA_BARD1 (circ_0001098) was up-regulated in breast cancer with the treatment of TCDD and the up-regulation of circRNA_BARD1 could restrain cell proliferation, block cell cycle and promote cell apoptosis.
|
30521417 |
2018 |